about
Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcersImpact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis.Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data.Dendritic cells from Crohn's disease patients show aberrant STAT1 and STAT3 signalingA novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosisIL23R in the Swedish, Finnish, Hungarian and Italian populations: association with IBD and psoriasis, and linkage to celiac diseaseVariants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3.A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention.Does oral α-galactosidase relieve irritable bowel symptoms?Family and twin studies in inflammatory bowel diseaseEvaluation of depression as a risk factor for treatment failure in chronic hepatitis C.Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection.Complete and incomplete intestinal metaplasia at the oesophagogastric junction: prevalences and associations with endoscopic erosive oesophagitis and gastritis.Immune activation in the small intestine in patients with rheumatoid arthritis.Foveolar hyperplasia at the gastric cardia: prevalence and associations.Immunohistochemical study of neuroendocrine cells at the gastric cardia mucosa.CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease.Helsinki alert of biodiversity and health.Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 InfectionIn Crohn's Disease, Anti-TNF-α Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells.Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.Quality of life following laparoscopic Nissen fundoplication: assessing short-term and long-term outcomes.A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis.Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease.Outcomes of patients hospitalized with peptic ulcer disease diagnosed in acute upper endoscopy.Cohort profile: the Nordic Antireflux Surgery Cohort (NordASCo).Biliary Anomalies in Patients With HNF1B Diabetes.Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study.Prognostic value of clinical variables and liver histology for development of fibrosis and cirrhosis in autoimmune hepatitis.Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents.Human leucocyte antigens B*08, DRB1*03 and DRB1*13 are significantly associated with autoimmune liver and biliary diseases in Finnish children.Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up.Increased short- and long-term mortality in 8146 hospitalised peptic ulcer patients.Incidence, survival and cause-specific mortality in alcoholic liver disease: a population-based cohort study.IL-23/IL-17 immunity as a hallmark of Crohn's disease.Screening primary sclerosing cholangitis and biliary dysplasia with endoscopic retrograde cholangiography and brush cytology: risk factors for biliary neoplasia.Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis.
P50
Q28213057-56BE5DB7-8EB4-4E4F-B5A4-DE39828251E0Q28729225-5452A3F4-D0FD-4FF2-89CD-A48132860E47Q28732828-1EB59BC3-F235-4172-BD6A-3CE700756F29Q30416155-B7B328DF-795C-43CB-92F2-37E3FAEBB223Q30651444-1D835F50-9E59-4081-A55E-7D894768F2AFQ31126452-DFF4382D-37CF-4937-8C8C-98507770AD9EQ31157282-B2933710-FD98-4E16-9FEF-9E03D6079A8CQ33403660-57435516-A597-4719-88C0-2F72AEA79964Q33413296-DD94340A-7CAC-493E-960F-08FECEBD0D9EQ33433931-925339DC-E6E0-4DF5-95DD-FF202D5D786EQ33465479-B48791ED-3967-4B8E-A584-11A217E5C1A7Q33996815-4ACB1082-7ABE-4015-A72F-8C28B88AC82FQ34129599-F4390CBE-9682-4455-85C8-F78859E908ACQ34775684-39120EFC-C587-4321-B522-7E621352F80EQ35357755-8BAF9BDA-9B40-4C64-B85C-DF856387EA73Q35553400-C305CC35-364D-44B3-9221-E638ABA139A8Q35586133-B45524A2-B902-439B-B0A1-04829E25E1CDQ35586383-591B49FB-C662-4034-8BA2-E421FB4AF533Q35595543-F359F58A-4215-495C-BBD1-23FC1AB4FE52Q35612185-8FE23CB6-F5C9-4AB0-BE22-54857E797D3CQ36014286-3565BD12-C94C-46AC-93E4-473BC3E980B5Q36063507-3CFEA2A0-7AA7-448A-AF5B-2A63F34E873BQ36519135-252934C4-5FF6-49EF-8A40-6B646B84DA8BQ36975063-4DFC6BEA-33D6-4A6F-AD44-0C8C8E68BBEDQ37166229-9D14FE9E-6B88-4988-A48C-3AE108240777Q37937183-4185150B-6763-4F60-B0D2-F267F89E711DQ38600307-0ECF75F6-BCAD-4A8B-8177-FB7B3271EA9DQ38672635-AEA133C3-C269-4087-95D0-EFFB6C0CD3A1Q38890149-C9C2CDE5-0584-4FC4-ADB5-231097DFDA4CQ38919832-F2BF8FBC-0E88-448C-BCAF-F047157CDA95Q38924675-419AFC2B-13E5-4070-B3B6-060E83AD0997Q39185918-07B828DA-4300-4FAB-906D-7B17EA1A1C9FQ39223252-97E11536-8B03-4847-9396-4E696C78CA1DQ39271143-C78386FA-F003-43C0-ABBC-4F492FF4979EQ39338382-CEBA549E-83ED-4F9E-AD39-73A27F6557AEQ39725436-9107A7B8-F3AF-48AD-83CC-EA55250974A5Q39764591-06AA6F0A-A353-4F77-ACB3-56FA265EC8C7Q39977129-35C8DD43-9BFE-4A66-B943-569D2578547AQ40064320-2CA858E7-9794-4922-A01A-7FB79E2145D5Q40094085-DBA52DCC-10F8-4903-9C53-BD38F6686BED
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Martti Färkkilä
@ast
Martti Färkkilä
@en
Martti Färkkilä
@es
Martti Färkkilä
@nl
Martti Färkkilä
@sl
type
label
Martti Färkkilä
@ast
Martti Färkkilä
@en
Martti Färkkilä
@es
Martti Färkkilä
@nl
Martti Färkkilä
@sl
prefLabel
Martti Färkkilä
@ast
Martti Färkkilä
@en
Martti Färkkilä
@es
Martti Färkkilä
@nl
Martti Färkkilä
@sl
P106
P21
P31
P496
0000-0002-0250-8559
P569
2000-01-01T00:00:00Z